[1]王华,都绮月,徐森楠,等.奥拉帕尼治疗铂敏感复发性卵巢癌疗效与安全性的Meta分析[J].华侨大学学报(自然科学版),2025,(2):223-229.[doi:10.11830/ISSN.1000-5013.202410004]
　WANG Hua,DU Qiyue,XU Sennan,et al.Meta-Analysis of Efficacy and Safety of Olaparib in Treating Platinum-Sensitive Recurrent Ovarian Cancer[J].Journal of Huaqiao University(Natural Science),2025,(2):223-229.[doi:10.11830/ISSN.1000-5013.202410004]
点击复制

奥拉帕尼治疗铂敏感复发性卵巢癌疗效与安全性的Meta分析()
分享到：

《华侨大学学报（自然科学版）》[ISSN:1000-5013/CN:35-1079/N]

卷:
期数:
2025年第2期
页码:
223-229
栏目:
出版日期:
2025-03-20

文章信息/Info

Title:
Meta-Analysis of Efficacy and Safety of Olaparib in Treating Platinum-Sensitive Recurrent Ovarian Cancer
文章编号:
1000-5013(2025)02-0223-07
作者:
王华1;  都绮月2; 3;  徐森楠2; 3;  王昆2;  吴小枫2;  张亮亮4;  邱彦2; 3;  杨嘉永2; 5
1. 华侨大学 华侨大学医院, 福建 厦门 361021;2. 厦门大学附属第一医院 药学部, 福建 厦门 361003;3. 厦门市手性药物重点实验室, 福建 厦门 361100;4. 华侨大学 先进碳转化技术研究院, 福建 厦门 361021;5. 厦门市药事综合管理专业质量控制中心, 福建 厦门 361003
Author(s):
WANG Hua1;  DU Qiyue2; 3;  XU Sennan2; 3;  WANG Kun2;  WU Xiaofeng2;  ZHANG Liangliang4;  QIU Yan2; 3;  YANG Jiayong2; 5
1. Huaqiao University Hospital, Huaqiao University, Xiamen 361021, China; 2. School of Medicine, The First Affiliated Hospital of Xiamen University, Xiamen 361003, China; 3. Xiamen Key Laboratory of Chiral Drugs, Xiamen 361100, China; 4. Academy of Advanced Carbon Conversion Technology, Huaqiao University, Xiamen 361021, China; 5. Xiamen Quality Control Center for Comprehensive Pharmaceutical Affairs Management Specialization, Xiamen 361003, China
关键词:
奥拉帕尼;  铂敏感复发性卵巢癌;  临床效果;  Meta分析
Keywords:
Olaparib;  platinum sensitive recurrent ovarian cancer;  clinical efficacy;  Meta-analysis
分类号:
R737.31
DOI:
10.11830/ISSN.1000-5013.202410004
文献标志码:
A
摘要:
系统评价奥拉帕尼治疗铂敏感复发性卵巢癌(PSROC)的临床效果及安全性,通过检索公共数据库中的相关研究,收集关于奥拉帕尼与单药化疗/安慰剂治疗PSROC的随机临床试验。应用RevMan 5.3进行Meta分析,最终纳入14篇文献。结果表明:试验组患者的临床缓解率、疾病控制率、无进展生存期均显著优于其他单药化疗药物;试验组患者的消化功能异常、骨髓抑制、神经毒性、心脏毒性及脱发等不良反应发生率显著低于其他单药化疗药物;奥拉帕尼在治疗PSROC方面表现出良好的疗效及较高的安全性。
Abstract:
The clinical efficacy and safety of Olaparib in treating platinum-sensitive recurrent ovarian cancer(PSROC)were evaluated systematically. The randomized clinical trials on Olaparib and single-agent chemotherapy/placebo in the treatment of PSROC were collected by searching relevant studies in public databases. Ultimately, 14 articles were incorporated by Meta-analysis using RevMan 5.3. The results showed that the clinical remission rate, disease control rate, and progression-free survival of patients in the experimental group were significantly better than other single-agent chemotherapy drugs. The incidence of adverse reactions such as gastrointestinal dysfunction, bone marrow suppression, neurotoxicity, cardiotoxicity, and alopecia of patients in the experimental group were significantly lower than other single-agent chemotherapy drugs. It is indicated that Olaparib shows good efficacy and higher safety in the treatment of PSROC.

参考文献/References:

[1] 布里斯托,阿姆斯特朗.卵巢癌[M].吴玉梅,张为远,译.北京: 人民卫生出版社,2011.
[2] 黄肖肖,李燕华.铂类敏感型复发性卵巢癌治疗的研究进展[J].安徽医药,2019,23(6):1069-1073.DOI:10.3969/j.issn.1009-6469.2019.06.003.
[3] 孔北华,刘继红,黄鹤,等.卵巢癌PARP抑制剂临床应用指南(2022版)[J].肿瘤综合治疗电子杂志,2022,8(3):64-77.DOI:10.12151/JMCM.2022.03-07.
[4] STANG A.Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in Meta-analyses[J].European Journal of Epidemiology,2010,25(9):603-605.DOI: 10.1007/s10654-010-9491-z.
[5] GREENLAND S,LONGNECKER M P.Methods for trend estimation from summarized dose-response data, with applications to Meta-analysis[J].American Journal of Epidemiology,1992,135(11):1301-1309.DOI:10.1093/oxfordjournals.aje.a116237.
[6] ORSINI N,LI R,WOLK A,et al.Meta-analysis for linear and nonlinear dose-response relations: Examples, an evaluation of approximations, and software[J].American Journal of Epidemiology,2012,175(1):66-73.DOI:10.1093/aje/kwr265.
[7] 崔雅馨,刘欣.奥拉帕利在铂敏感复发性卵巢癌维持治疗中的临床价值研究[J].潍坊医学院学报,2020,42(2):114-117.DOI:10.16846/j.issn.1004-3101.2020.02.010.
[8] 徐才慧,牛爱琴,郭银谋.奥拉帕尼联合紫杉醇、顺铂化疗方案治疗铂敏感复发性卵巢癌的效果[J].河南医学研究,2021,30(25):4747-4750.DOI:10.3969/j.issn.1004-437X.2021.25.044.
[9] 权瑞泉,张丽,匡黎,等.奥拉帕尼联合贝伐珠单抗治疗复发性铂类敏感卵巢癌患者的疗效及对血清HE4、 CA125、 CTC水平的影响[J].国际肿瘤学杂志,2020,47(10):606-610.DOI:10.3760/cma.j.cn371439-20191116-00086.
[10] 路平,郭玉琪.奥拉帕尼联合贝伐珠单抗在复发性铂类敏感卵巢癌患者中的疗效观察[J].中国合理用药探索,2020,17(7):77-82.DOI:10.3969/j.issn.2096-3327.2020.7.019.
[11] PUJADE-LAURAINE E,LEDERMANN J A,SELLE F,et al.Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation(SOLO2/ENGOT-Ov21): A double-blind, randomised, placebo-controlled, phase 3 trial[J].Lancet Oncology,2017,18(9):1274-1284.DOI:10.1016/S1470-2045(17)30469-2.
[12] POVEDA A,FLOQUET A,LEDERMANN J A,et al.Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation(SOLO2/ENGOT-Ov21): A final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial[J].Lancet Oncology,2021,22(5):620-631.DOI:10.1016/S1470-2045(21)00073-5.
[13] PENSON R T,VALENCIA R V,CIBULA D,et al.Olaparib versus nonplatinum chemotherapy in patients with platinum-sensitive relapsed ovarian cancer and a germline BRCA1/2 Mutation(SOLO3): A randomized phase Ⅲ trial[J].Journal of Clinical Oncology,2020,38(11):1164-1174.DOI:10.1200/JCO.19.02745.
[14] LEDERMANN J,HARTER P,GOURLEY C,et al.Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial[J].Lancet Oncology,2014,15(8):852-861.DOI:10.1016/S1470-2045(14)70228-1.
[15] OZA A M,CIBULA D,BENZAQUEN A O,et al.Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: A randomised phase 2 trial[J].Lancet Oncology,2015,16(1):87-97.DOI:10.1016/S1470-2045(14)71135-0.
[16] LEDERMANN J A,HARTER P,GOURLEY C,et al.Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: An updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial[J].Lancet Oncology,2016,17(11):1579-1589.DOI:10.1016/S1470-2045(16)30376-X.
[17] FRIEDLANDER M,GEBSKI V,GIBBS E,et al.Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation(SOLO2/ENGOT Ov-21): A placebo-controlled, phase 3 randomised trial[J].Lancet Oncology,2018,19(8):1126-1134.DOI:10.1016/S1470-2045(18)30343-7.
[18] PEREZ-FIDALGO J A,CORTéS A,GUERRA E,et al.Olaparib in combination with pegylated liposomal doxorubicin for platinum-resistant ovarian cancer regardless of BRCA status: A GEICO phase Ⅱ trial(ROLANDO study)[J].European Society for Medical Oncology,2021,6(4):100212.DOI:10.1016/J.ESMOOP.2021.100212.
[19] MATULONIS U A,HARTER P,GOURLEY C,et al.Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for postprogressionpoly(adenosine diphosphate ribose)polymerase inhibitor therapy[J].Cancer,2016,122(12):1844-1852.DOI:10.1002/cncr.29995.
[20] COLOMBO N,TOMAO F,PANICI P B,et al.Randomized phase Ⅱ trial of weekly paclitaxel vs. cediranib-olaparib(continuous or intermittent schedule)in platinum-resistant high-grade epithelial ovarian cancer[J].Gynecologic Oncology,2022,164(3):505-513.DOI:10.1016/J.YGYNO.2022.01.015.
[21] 陈慧,周思园,孙振球.常见妇科三大恶性肿瘤的流行及疾病负担研究现状[J].中国现代医学杂志,2015,25(6):108-112.
[22] 朱俊,吴小华.2020年度妇科恶性肿瘤最新研究进展及展望[J].中国癌症杂志,2021,31(4):250-256.DOI:10.19401/j.cnki.1007-3639.2021.04.002.
[23] BOCHUM S,BERGER S,MARTENS U M.Olaparib[J].Recent Results in Cancer Research,2018,211:217-233.DOI:10.1007/978-3-319-91442-8.
[24] POVEDA A,FLOQUET A,LEDERMANN J A,et al.Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsedovarian cancer and a BRCA1/2 mutation(SOLO2/ENGOT-Ov21): A final analysis of a double-blind, randomized, placebo-controlled, phase 3 trial[J].Lancet Oncology,2021,22(5):620-631.DOI:10.1016/S1470-2045(21)00073-5.
[25] 冯征.PARP 抑制剂用于铂敏感复发卵巢癌患者维持治疗的血液学毒性概述[J].中国癌症杂志,2020,30(4):299-304.DOI:10.19401/j.cnki.1007-3639.2020.04.009.

备注/Memo

备注/Memo:
收稿日期: 2024-10-12
通信作者: 杨嘉永(1973-),男,主任药师,主要从事临床药学的研究。E-mail:yjy_158@163.com。
基金项目: 白求恩公益基金“耀动神州-药学科研能力建设基金”资助项目(Z04JKM2023E040)https://hdxb.hqu.edu.cn/
更新日期/Last Update: 2025-03-20